1. Home
  2. NCRA vs NERV Comparison

NCRA vs NERV Comparison

Compare NCRA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$1.23

Market Cap

13.2M

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$4.04

Market Cap

14.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
NERV
Founded
2002
2007
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
14.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NCRA
NERV
Price
$1.23
$4.04
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
49.7K
70.4K
Earning Date
04-01-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,106,275.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$1.15
52 Week High
$2.40
$12.46

Technical Indicators

Market Signals
Indicator
NCRA
NERV
Relative Strength Index (RSI) 56.94 51.05
Support Level $0.83 $3.64
Resistance Level $0.95 $4.17
Average True Range (ATR) 0.10 0.34
MACD 0.04 -0.00
Stochastic Oscillator 85.11 65.97

Price Performance

Historical Comparison
NCRA
NERV

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Share on Social Networks: